Clinical Trials Logo

Bone Neoplasms clinical trials

View clinical trials related to Bone Neoplasms.

Filter by:

NCT ID: NCT05595603 Recruiting - Clinical trials for Giant Cell Tumor of Bone

Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage

Start date: March 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional curettage surgery. The hypothesis is that patients with local administration of zoledronic acid to the bone cement has lower relapse rate compared those with traditional bone cement(gentamicin PMMA ).

NCT ID: NCT05524064 Recruiting - Clinical trials for Bone Metastases in the Thorax

FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax

FAST-02
Start date: March 8, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess toxicities of FLASH radiotherapy treatment and pain relief in subjects with painful thoracic bone metastases. FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.

NCT ID: NCT05480189 Not yet recruiting - Clinical trials for Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis

Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study

Start date: August 30, 2022
Phase:
Study type: Observational

non-intervention、real world study; Effect of timing and regular treatment of zoledronic acid on the incidence of SREs in breast cancer patients

NCT ID: NCT05475938 Completed - Bone Tumors Clinical Trials

Application of Painting Analysis and Psychotherapy in Children With Bone Tumors

Start date: October 20, 2021
Phase: N/A
Study type: Interventional

In the population suffering from cancer, children and teenagers are in the majority. For children with rapid development of body and mind, with the change of cognitive ability, they will feel anxiety and fear about the expected potential negative events. Painting art therapy is a kind of non-verbal psychological therapy through the interaction between the painter, the painting work and the therapist, with the painting creation activity as the intermediary. The purpose is to develop symbolic language, touch the inner subconscious, and integrate into the personality, so as to produce cognitive and behavioral changes. Painting therapy and psychological analysis can improve the treatment compliance of children bone tumor patients, make psychological nursing and health education of patients more targeted, and promote the cooperation between medical care and patients.

NCT ID: NCT05466812 Not yet recruiting - Bone Metastases Clinical Trials

Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Start date: July 13, 2022
Phase: Phase 4
Study type: Interventional

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

NCT ID: NCT05427825 Recruiting - Clinical trials for Metastatic Bone Tumor

ERAS Anesthetic Care for Metastatic Spine Cancer Resection

Start date: July 2022
Phase: N/A
Study type: Interventional

Spinal metastases account for 60% of all malignant bone metastases and represent a medically important treatment goal. For patients with malignant tumors diagnosed at this stage, performing En bloc spondylectomy with wide margin of resection facilitate the improvement in quality of life including ambulatory ability, daily activities independence and attenuation of bone pain. However, En bloc spondylectomy is a major operation with long operation time and frequent hemodynamic instability during the operation. Therefore, the anesthetic care plays an important role and an enhanced recovery after surgery (ERAS) is the goal. For the ERAS anesthesia protocol for En bloc spondylectomy, we propose two major components to achieve this goal: (1) an encephalographic spectrum guided multimodal anesthesia combined with ultrasound-guided nerve block and (2) the advanced machine-learning algorithm index, namely the hypotension predictive index (HPI) guided hemodynamic protocol.

NCT ID: NCT05406063 Recruiting - Pain Clinical Trials

Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases

SMILE
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

To investigate, whether multi-fraction stereotactic body radiation therapy (SBRT) within 3 treatment fractions is non-inferior to the current standard of care of 5 fraction SBRT regarding pain response at 3 months after radiotherapy.

NCT ID: NCT05402865 Completed - Clinical trials for Giant Cell Tumor of Bone

A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone

Start date: November 10, 2021
Phase:
Study type: Observational

This is a retrospective observational real-world study, which evaluates the efficacy and safety of denosumab and non-denosumab therapies in the treatment of Chinese populations of surgically unsalvageable or severe post-surgery morbidity associated giant cell tumor of bone (GCTB), collectively referred to as unresectable GCTB, during 2013-2021 in three medical centers, serving as the external control for a single arm phase Ib/II trial on JMT103 treatment of GCTB. 301 patients were enrolled and divided into 2 groups according to their actual previous exposures. Group 1 (n=135) was denosumab group. Group 2 (n=166) included two types of exposures other than denosumab: other anti-GCTB drug therapies, or no therapy on GCTB patients. The dosage, route, frequency and other administration methods was collected according to the actual previous treatment records. The primary outcome measure was the tumor response rate [radiographic tumor response (CR/PR evaluated by ICDs or EORTC criteria) within 12 weeks, or at least 90% reduction of osteoclast like giant cells compared with baseline]. The key secondary endpoint was the tumor response rate [radiographic tumor response (CR/PR evaluated by ICDS or EORTC criteria), or at least 90% reduction of osteoclast like giant cells compared with baseline]. Other secondary Outcome Measures include: proportion of patients whose tumors was surgically resectable; median duration of tumor response (DOR), disease control rate (DCR), and time to disease progression (TTP); and types and proportion of key adverse reactions.

NCT ID: NCT05397522 Not yet recruiting - Tumor Clinical Trials

The Effects of Observer Presence and Type on Patients' Perception of Exercise After Bone Tumor Resection-A Qualitative Study

Start date: August 15, 2022
Phase: N/A
Study type: Interventional

The primary aim of the study is to investigate the effects of supervised exercise, telerehabilitation and home-based exercise on patient perception in patients who have undergone bone tumor resection. The secondary aim of the study is to identify the barriers to starting exercise in these patients.

NCT ID: NCT05395741 Recruiting - Osteosarcoma Clinical Trials

Regorafenib in Patients With Refractory Primary Bone Tumors

Regbone
Start date: April 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options using advanced molecular diagnostics for patients who have not responded to the standard therapeutic regimen, and to introduce modern diagnostics for risk stratification and for the use in molecularly targeted therapies.